1. Home
  2. RNTX vs APT Comparison

RNTX vs APT Comparison

Compare RNTX & APT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.17

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Pro Tech Ltd.

APT

Alpha Pro Tech Ltd.

HOLD

Current Price

$6.69

Market Cap

51.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNTX
APT
Founded
2001
1983
Country
United States
Canada
Employees
10
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.7M
51.4M
IPO Year
N/A
1997

Fundamental Metrics

Financial Performance
Metric
RNTX
APT
Price
$1.17
$6.69
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
1.1M
104.2K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.07
Revenue
N/A
$59,142,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$92.57
Revenue Growth
N/A
2.25
52 Week Low
$1.00
$4.25
52 Week High
$2.22
$6.89

Technical Indicators

Market Signals
Indicator
RNTX
APT
Relative Strength Index (RSI) 40.78 85.55
Support Level $1.08 $4.50
Resistance Level $1.30 N/A
Average True Range (ATR) 0.15 0.35
MACD -0.05 0.25
Stochastic Oscillator 15.45 70.50

Price Performance

Historical Comparison
RNTX
APT

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About APT Alpha Pro Tech Ltd.

Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply: consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment and synthetic roof underlayment accessories.

Share on Social Networks: